Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide
Rodney J. Ellis, Hang Zhou, Edward Y. Kim, Pingfu Fu, Deborah A. Kaminsky, Bruce Sodee, Valdir Colussi, Waseet Z. Vance, John P. Spirnak, Carolyn Kim, Martin I. Resnick
Dive into the research topics of 'Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide'. Together they form a unique fingerprint.